Mucositis Clinical Trial
Official title:
A Multi-institutional, Randomized Parallel Controlled, Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Amifostine Every-other-day Regimen and Everyday Regimen From Monday to Friday
RATIONALE
- Radiotherapy is the primary therapeutic strategy for nasopharyngeal carcinoma.
- Radiotherapy may cause adverse effect such as xerostomia and mucositis.
- Amifostine has the ability of protecting the normal tissue but also has some side
effects.
PURPOSE
- This phase II trial is to study the protecting effect and safety of different Amifostine
regimens in patients with nasopharyngeal carcinoma.
RATIONALE: Nasopharyngeal carcinoma is a kind of malignant tumor which is treated primarily
by radiation therapy. This therapeutic strategy often causes adverse effects such as
dysfunction of salivary gland and lesion of oral mucosa. With concurrent chemotherapy, it may
also cause toxicity to kidney, bone marrow, and other organs or tissues. When administered
prior to chemoradiotherapy, Amifostine has been proved to has the ability of protecting the
normal from these adverse effects so as to improve the patient tolerance. However, there are
also some side effects of Amifostine itself, such as nausea, vomiting and hypotension,
especially when high dose is applied.
PURPOSE: This phase II randomized controlled trial is to study the protecting effect and its
safety of Amifostine every-other-day regimen compared with standard everyday regimen on
adverse effects such as myelosuppression, xerostomia and mucositis, in patients with
nasopharyngeal carcinoma Stage T1-T4, N0-N3, M0 and undergoing concurrent chemoradiotherapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02252926 -
Local Anesthetic Treatment of Oral Pain in Patients With Mucositis
|
Phase 2 | |
| Completed |
NCT01155609 -
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer
|
N/A | |
| Completed |
NCT00357942 -
Topical Morphine for Stomatitis-related Pain Induced by Chemotherapy
|
Phase 4 | |
| Completed |
NCT00360685 -
Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX
|
N/A | |
| Completed |
NCT04586491 -
The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients
|
N/A | |
| Withdrawn |
NCT02589860 -
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
|
||
| Not yet recruiting |
NCT02506231 -
The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome
|
Phase 2/Phase 3 | |
| Completed |
NCT02639377 -
Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis and Gingivitis
|
Phase 2 | |
| Completed |
NCT02605382 -
Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis
|
Phase 2 | |
| Terminated |
NCT02575313 -
The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00956254 -
Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
|
Phase 3 | |
| Completed |
NCT00584597 -
A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis
|
Phase 1 | |
| Enrolling by invitation |
NCT05590117 -
Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer
|
Early Phase 1 | |
| Completed |
NCT05635929 -
Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.
|
N/A | |
| Completed |
NCT05181943 -
Effectiveness of Photo-biomodulation in the Treatment of Chemotherapy Induced Mucositis
|
N/A | |
| Completed |
NCT03713567 -
Clinical, Immunological and Microbiological Evaluation of Experimental Gingivitis and Peri-implant Mucositis
|
N/A | |
| Completed |
NCT02671812 -
Outcome After Dental Implant Treatment
|
||
| Terminated |
NCT02273752 -
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
|
Phase 2 | |
| Recruiting |
NCT01707641 -
Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer
|
Phase 4 | |
| Completed |
NCT01015183 -
Prevention Chemotherapy Induced Mucositis by Zinc Sulfate
|
Phase 2/Phase 3 |